Ultimate magazine theme for WordPress.

Cannabis drug developer IncanneX withdraws US IPO


the company said it planned to offer 2.6M ADSs which each ADS representing 25 ordinary shares. In the Dec. 7 filing representing 65M ordinary shares. Underwriters would be granted a 30-day option to purchase up to 390 and inflammatory bowel disease. Incannex had filed an amended F-1 on Dec. 7 stating that it intended to offer up to $30.9M in shares and warrants. The shares would be offered as American Depositary Shares Roth Capital Partners was serving as underwriter for the deal. IXHL is the latest company to pull its IPO as investor enthusiasm for new issues wanes. On Thursday according to Barrons . Seeking Alpha contributor Donovan Jones noted in a column on the company last year that IXHL was “pursuing an ambitious development program but is thinly capitalized.”


Leave A Reply

Your email address will not be published.